Inhaled nitric oxide therapy in premature newborns

Current Opinion in Pediatrics

Volumn 18, Issue 2, 2006, Pages 107-111

  Kinsella, John P ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

Bronchopulmonary dysplasia; Intraventricular hemorrhage; Nitric oxide; Prematurity; Respiratory distress syndrome

Indexed keywords

NITRIC OXIDE;

CLINICAL TRIAL; DISEASE SEVERITY; EXTRACORPOREAL OXYGENATION; HUMAN; HYPOXEMIA; LUNG DYSPLASIA; OUTCOMES RESEARCH; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; RISK BENEFIT ANALYSIS;

ADMINISTRATION, INHALATION; BRONCHOPULMONARY DYSPLASIA; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; NITRIC OXIDE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY INSUFFICIENCY;

EID: 33646523863     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000193291.09894.6c     Document Type: Review

References (41)

1. Clark RH, Kueser TJ, Walker MW, et al. Randomized, controlled trial of low-dose inhaled nitric oxide treatment of persistent pulmonary hypertension of the newborn. N Engl J Med 2000; 17; 342 (7):469-474.
2. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997; 336:597-604.
3. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276:357-368.
4. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340:819-820.
5. Roberts JD, Polaner DM, Lang P, et al. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340:818-819.
6. Abman SH, Kinsella JP, Schaffer MS, Wilkening RB. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics 1993; 92:606-609.
7. Kinsella JP, Ivy DD, Abman SH. Ontogeny of NO activity and response to inhaled NO in the developing ovine pulmonary circulation. Am J Physiol 1994; 267:H1955-H1961.
8. Kinsella JP, Ivy DD, Abman SH. Inhaled nitric oxide lowers pulmonary vascular resistance and improves gas exchange in severe experimental hyaline membrane disease. Pediatr Res 1994; 36:402-408.
9. Kanwar S, Kubes P. Nitric oxide is an antiadhesive molecule for leukocytes. N Horiz 1995; 3:93-104.
10. Kinsella JP, Parker TA, Galan H, et al. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 1997; 41:457-463.
11. Merritt TA, Cochrane CG, Holcomb K, et al. Elastase and α-1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. J Clin Invest 1983; 72:656-666.
12. Ogden BE, Murphy S, Saunders GC, Johnson JD. Lung lavage of newborns with respiratory distress syndrome: prolonged neutrophil influx is associated with bronchopulmonary dysplasia. Chest 1983; 83:31-33.
13. Speer CP, Ruess D, Harms K, et al. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993; 91:794-799.
14. Brus F, Van Oeveren W, Heikamp A, et al. Leakage of protein into lungs of preterm ventilated rabbits is correlated with activation of clotting, complement, and polymorphonuclear leukocytes in plasma. Pediatr Res 1996; 39:958-965.
15. Zimmerman JJ. Bronchoalveolar inflammatory pathophysiology of bronchopulmonary dysplasia. Clin Perinatol 1995; 22:429-456.
16. Storme L, Zerimech F, Riou Y, et al. Inhaled nitric oxide neither alters oxidative stress parameters nor induces lung inflammation in premature lambs with moderate hyaline membrane disease. Bio Neonatol 1998; 73:172-181.
17. Nelin LD, Welty SE, Morrisey JF, et al. Nitric oxide increases the survival of rats with a high oxygen exposure. Pediatr Res 1998; 43:727-732.
18. Gutierrez HH, Nieves B, Chumley P, et al. Nitric oxide regulation of superoxide-dependent lung injury: oxidant-protective actions of endogenously produced and exogenously administered nitric oxide. Free Radic Biol Med 1996; 21:43-52.
19. Issa A, Lappalainen U, Kleinman M, et al. Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits. Pediatr Res 1999; 45:247-254.
20. MacRitchie AN, Albertine KH, Sun J, et al. Reduced endothelial nitric oxide synthase in lungs of chronically ventilated preterm lambs. Am J Physiol Lung Cell Mol Physiol 2001; 281:L1011-L1020.
21. Afshar S, Gibson LL, Yuhanna IS, et al. Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003; 284:L749-L758.
22. Tang JR, Markham NE, Balasubramaniam V, et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004; 287:L344-L351.
23. Tang JR, Markham NE, Lin YJ, et al. Inhaled NO attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 2004; 287:L344-L351. Exposure of newborn rats to hyperoxia impairs alveolarization and vessel growth. In this study, newborn rats exposed to hyperoxia had reduced lung VEGF, VEGFR-2, and eNOS protein expression and decreased distal lung growth. Inhaled NO treatment restored distal lung growth.
24. McCurnin DC, Pierce RA, Chang LY, et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung 2005; 288:450-459. Pulmonary NO production is decreased in a baboon model of chronic lung disease after premature birth. In this study, premature baboons were mechanically ventilated for 14 days and treated with 5 ppm INO. Inhaled NO improved early pulmonary function and altered extracellular matrix deposition compared to controls.
25. Peliowski A, Finer NN, Etches PC, et al. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J Pediatr 1995; 126:450-453.
26. Van Meurs KP, Rhine WD, Asselin JM, Durand DJ. Response of premature infants with severe respiratory failure to inhaled nitric oxide. Pediatr Pulmonol 1997; 24:319-323.
27. Hogman M, Frostell C, Arnberg H, Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet 1993; 341:1664-1665.
28. Simon DI, Stamler JS, Jaraki O, et al. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb 1993; 13:791-799.
29. George TN, Johnson KJ, Bates JN, Segar JL. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr 1998; 132:731-734.
30. Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high-risk preterm infants. Arch Dis Child 1997; 77:F185-F190.
31. Kinsella JP, Walsh WF, Bose CL, et al. Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial. Lancet 1999; 354:1061-1065.
32. The Franco-Belgium Collaborative NO Trial Group. Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trial. Lancet 1999; 354:1066-1071.
33. Hascoet JM, Fresson J, Claris O, et al. The safety and efficacy of nitric oxide therapy in premature infants. J Pediatr 2005; 146:318-323. Report of an unblinded trial of INO treatment in premature newborns. No differences were found in major outcome measures or adverse events.
34. Finer NN. Inhaled nitric oxide for preterm infants: A therapy in search of an indication? The search continues. J Pediatr 2005; 146:301-302.
35. Hamon I, Fresson J, Nicolas MB, et al. Early inhaled nitric oxide improves oxidative balance in very preterm infants. Pediatr Res 2005; 57:637-643. Serum samples from patients enrolled in the Hascoet trial [33] were analyzed for markers of oxidant stress. Inhaled NO improved oxidative balance compared with controls.
36. Field D, Elbourne D, Truesdale A, et al. Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: The INNOVO multicentre randomized controlled trial. Pediatrics 2005; 115:926-936. An unblinded trial of INO in 108 premature newborns with severe lung disease. No differences were found in major outcome measures or adverse events.
37. Field DJ. Nitric oxide still no consensus. Early Hum Dev 2005; 81:1-4.
38. Schreiber MD, Gin-Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349:2099-2107.
39. Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 2005; 353:13-22. The largest RCT of INO in premature newborns published to date. There were no differences in major outcome measures. In post-hoc analyses, however, INO treatment decreased the incidence of death/BPD in infants with birthweights greater than 1000 g, and infants with birthweights no more than 1000 g had higher mortality and increased rates of severe ICH.
40. Mestan KK, Marks JD, Hecox K, et al. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med 2005; 353: 23-32. In this single-center, masked, RCT, 207 patients were randomized to treatment with INO versus control. Neurodevelopmental outcomes were studied in 138 children at 2 years of age. Treatment with INO in the newborn period was associated with improved neurodevelopmental outcomes.
41. ••].